| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.077 | 0.06 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.06 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.091 | 0.07 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.07 |